

Issued by JPAC: 15 July 2020	Implementation: To be determined by each Service
------------------------------	--

Change Notification UK National Blood Services No. 40 - 2020

Tamiflu® and Relenza®

These changes apply to ALL the Tissue and Cells Donor Selection Guidelines

Tamiflu®

Please make the following changes to this topic:

<i>See</i>	Infection - Acute
<i>Approved Name</i>	Oseltamivir
<i>Obligatory</i>	Must not donate if: a) Was taking Tamiflu® as treatment for influenza. b) At any time in the seven days prior to, or while taking Tamiflu®, the donor had symptoms of influenza, (a temperature of greater than 38°C, or a history of fever and two or more of the following symptoms: cough, headache, runny nose, diarrhoea/vomiting).
<i>Discretionary</i>	If the potential donor was taking Tamiflu® as prophylaxis, they had not been advised to be confined to home and did not have any symptoms of influenza, accept.
<i>See if Relevant</i>	Infection – Acute
<i>Additional Information</i>	Tamiflu® is a viral neuraminidase inhibitor (neuraminidase is an enzyme that helps the virus spread from cell to cell). It is used to treat influenza and for post-exposure prophylaxis of influenza. It appears to be a very safe drug with little evidence for teratogenic (potential to cause birth defects) or mutagenic (potential to cause malignancy) effect.
<i>Reason for Change</i>	This is a new entry. This entry now redirects to the 'Infection – Acute' entry.

Relenza®

Please make the following changes to this topic:

\Continued

See	Infection - Acute
Approved Name	Zanamivir
Obligatory	<p>Must not donate if:</p> <p>a) Was taking Relenza® as treatment for influenza.</p> <p>b) At any time in the seven days prior to, or while taking Relenza®, the donor had symptoms of influenza, (a temperature of greater than 38°C, or a history of fever and two or more of the following symptoms: cough, headache, runny nose, diarrhoea/vomiting).</p>
Discretionary	If the potential donor was taking Relenza® as prophylaxis, they had not been advised to be confined to home and did not have any symptoms of influenza, accept.
See if Relevant	Infection – Acute
Additional Information	Relenza® is a viral neuraminidase inhibitor (neuraminidase is an enzyme that helps the virus spread from cell to cell). It is used to treat influenza and for post-exposure prophylaxis of influenza. It appears to be a very safe drug with little evidence for teratogenic (potential to cause birth defects) or mutagenic (potential to cause malignancy) effect.
Reason for Change	This is a new entry. This entry now redirects to the 'Infection – Acute' entry.

Sheila MacLennan

Dr Sheila MacLennan
Professional Director - Joint UKBTS Professional Advisory Committee
 ☎ Direct Dial: (0113) 820 8638 ✉ sheila.maclennan@nhsbt.nhs.uk